Evaluation of the safety, reactogenicity and immunogenicity of FluBlok® trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age☆
- 9 March 2011
- Vol. 29 (12) , 2272-2278
- https://doi.org/10.1016/j.vaccine.2011.01.039
Abstract
No abstract availableKeywords
This publication has 0 references indexed in Scilit: